Personalised antiplatelet therapy for peripheral arterial disease. 1.0
Research type
Research Study
Full title
Personalised antiplatelet therapy for patients with symptomatic peripheral arterial disease (PANTHER – PAD) .
IRAS ID
293977
Contact name
Matthew J. Bown
Contact email
Sponsor organisation
University of Leicester
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Peripheral arterial disease (PAD) is a condition where the blood vessels in the legs get blocked. It affects one out of every five adults over the age of 65. As it is the main cause of amputations, the NHS performs over 20,000 operations every year to prevent them.
People with PAD benefit from tablets to thin their blood as this improves outcomes after surgery and prevents heart attacks and strokes. The main tablets for this purpose are aspirin and clopidogrel.
These work in most people, but up to a third of patients do not get any benefit from them, as their bodies cannot process them. We call this resistance to therapy (RT).
Because blood thinning is particularly important after operations people with RT may be at higher risk of their operation failing leading to amputation and/or problems such as heart attacks and strokes.
Testing for RT has not traditionally been performed because it requires complex laboratory procedures. Recent development in technology now mean that bedside tests are available for RT.
We will use a simple beside test for RT in patients with severe PAD. We will use this test to see how many of these patients have RT and whether this affects their risk of complications after an operation.
If we find that RT does affect outcomes for patients with PAD, the information obtained will be used to plan future research to determine if changing blood thinning therapy in people with CR improves their outcomes after surgery.
REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
21/EM/0260
Date of REC Opinion
29 Dec 2021
REC opinion
Further Information Favourable Opinion